Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration.

ABSTRACT:

Purpose

To analyze the risk factors associated with emerging intraocular inflammation (IOI) after intravitreal brolucizumab injection (IVBr) to treat age-related macular degeneration (AMD).

Methods

This study included 93 eyes of 90 patients. The incidence of emerging IOI was analyzed. The patients were classified into IOI or non-IOI groups, and background clinical characteristics in each group were compared.

Results

IOI occurred in 14 eyes of 14 cases (16%; five women, nine men [5:9]; IOI group) after IVBr; contrastingly, no IOI occurred in 76 patients (10 women, 66 men [10:66]; non-IOI group). The mean ages in IOI and non-IOI groups were 79.4 ± 8.1 and 73.8 ± 8.9 years old, respectively, and the average age in the IOI group was significantly higher than that in the n

SUBMITTER: Mukai R 

PROVIDER: S-EPMC8648104 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature